

## CD30/TNFRSF8 Protein, Human, Recombinant (His & Avi), Biotinylated

### General Information

Synonyms:	Ki-1;CD30;D1S166E;tumor necrosis factor receptor superfamily, member 8
Protein Construction:	Phe19-Lys379
Species:	Human
Expression Host:	HEK293 Cells
Accession:	P28908-1
Molecular Weight:	41.3 kDa (Predicted); 70-100 kDa (Reducing conditions due to glycosylation)

### QC Testing

Biological Activity:	Immobilized Anti-CD30 Antibody, hFc Tag at 0.5µg/ml (100µl/well) on the plate. Dose response curve for Biotinylated Human CD30, His Tag with the EC50 of 11.5ng/ml determined by ELISA (QC Test).
Purity:	> 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC
Endotoxin:	< 1.0 EU/µg of the protein as determined by the LAL method.
Formulation:	Lyophilized from 0.22µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.

### Preparation and Storage

#### Reconstitution:

Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 µg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing.

#### Stability & Storage:

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Actual storage temperature shall be subject to the COA.

#### Shipping:

In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.

### Protein Background

The transmembrane receptor CD30 (TNFRSF8) and its ligand CD30L (CD153, TNFSF8) are members of the tumor necrosis factor (TNF) superfamily and display restricted expression in subpopulations of activated T- and B-cells in nonpathologic conditions. CD30 expression is upregulated in various hematological malignancies, including Reed-Sternberg cells in Hodgkin's disease (HD), anaplastic large cell lymphoma (ALCL) and subsets of Non-

Hodgkin's lymphomas (NHLs).

### Reference

- Rossi FM, et al. (2001) CD30L up-regulates CD30 and IL-4 expression by T cells. *FEBS Lett.* 508(3): 418-22.
- Trovato M, et al. (2001) Expression of CD30 ligand and CD30 receptor in normal thyroid and benign and malignant thyroid nodules. *Thyroid.* 11(7): 621-8.
- Ekstrom ES, et al. (2001) Presence of CD30(+) and CD30L(+) cells in human placenta and soluble CD30 levels in cord blood are independent of maternal atopy. *Placenta.* 22(4): 372-9.
- Tang C, et al. (2008) A novel role of CD30L/CD30 signaling by T-T cell interaction in Th1 response against mycobacterial infection. *J Immunol.* 181(9): 6316-27.
- Sun X, et al. (2008) A critical role of CD30 ligand/CD30 in controlling inflammatory bowel diseases in mice. *Gastroenterology.* 134(2): 447-58.
- Oflazoglu E, et al. (2009) Targeting CD30/CD30L in Oncology and Autoimmune and Inflammatory Diseases. *Adv Exp Med Biol.* 647: 174-85.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286    E\_mail: info@targetmol.com    Address: 34 Washington Street, Wellesley Hills, MA 02481